Biochemical analyses of amyloid deposition in dialysis-related amyloidosis patients showed that ΔN6, a truncated variant of β2M lacking the N-terminal hexapeptide1IQRTPK6, accounts for approximately 30% of the deposition [28–30]. This evidence concerns the gene B2M and amyloidosis.